Brief: Cytodyn Inc Says Plans To Initiate A Registration-Directed Study Of Leronlimab Monotherapy Indication

Cytodyn

05/03/2021 23:04

March 5 (Reuters) - Cytodyn Inc  CYDY.PK :
    * CYTODYN’S PHASE 3 TRIAL DEMONSTRATES SAFETY, A 24%
REDUCTION IN
MORTALITY AND FASTER HOSPITAL DISCHARGE FOR MECHANICALLY
VENTILATED CRITICALLY ILL COVID-19 PATIENTS TREATED WITH
LERONLIMAB
    * CYTODYN INC - EXPECTS TO REFILE ITS BLA IN FIRST HALF OF
CALENDAR YEAR 2021
    * CYTODYN INC - HAS BEEN WORKING DILIGENTLY TO REFILE ITS
BLA FOR
THIS HIV COMBINATION THERAPY SINCE RECEIVING A REFUSAL TO FILE
IN JULY 2020
    * CYTODYN INC - PLANS TO INITIATE A REGISTRATION-DIRECTED
STUDY OF
LERONLIMAB MONOTHERAPY INDICATION

Source text for Eikon:  ID:nGNX9Z22Gn 
Further company coverage:  CYDY.PK 

 ((reuters.briefs@thomsonreuters.com;))